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Abstract
Background: During a four-year action research project (2003-2007), a program targeting all type 2 diabetes patients was 
implemented in a well-defined geographical region in Belgium. The implementation of the program resulted in an increase 
of the overall Assessment of Chronic Illness Care (ACIC) score from 1.45 in 2003 to 5.5 in 2007. The aim of the follow-up study 
in 2008 was to assess the effect of the implementation of Chronic Care Model (CCM) elements on the quality of diabetes care 
in a country where the efforts to adapt primary care to a more chronic care oriented system are still at a starting point.
Methods: A quasi-experimental study design involving a control region with comparable geographical and socio-
economic characteristics and health care facilities was used to evaluate the effect of the intervention in the region. In 
collaboration with the InterMutualistic Agency (IMA) and the laboratories from both regions a research database was 
set up. Study cohorts in both regions were defined by using administrative data from the Sickness Funds and selected 
from the research database. A set of nine quality indicators was defined based on current scientific evidence. Data were 
analysed by an institution experienced in longitudinal data analysis.
Results: In total 4,174 type 2 diabetes patients were selected from the research database; 2,425 patients (52.9% 
women) with a mean age of 67.5 from the intervention region and 1,749 patients (55.7% women) with a mean age of 
67.4 from the control region. At the end of the intervention period, improvements were observed in five of the nine 
defined quality indicators in the intervention region, three of which (HbA1c assessment, statin therapy, cholesterol 
target) improved significantly more than in the control region. Mean HbA1c improved significantly in the intervention 
region (7.55 to 7.06%), but this evolution did not differ significantly (p = 0.4207) from the one in the control region (7.44 
to 6.90%). The improvement in lipid control was significantly higher (p = 0.0021) in the intervention region (total 
cholesterol 199.07 to 173 mg/dl) than in the control region (199.44 to 180.60 mg/dl). The systematic assessment of 
long-term diabetes complications remained insufficient. In 2006 only 26% of the patients had their urine tested for 
micro-albuminuria and only 36% had consulted an ophthalmologist.
Conclusion: Although the overall ACIC score increased from 1.45 to 5.5, the improvement in the quality of diabetes care was 
moderate. Further improvements are needed in the CCM components delivery system design and clinical information 
systems. The regional networks, as they are financed now by the National Institute for Health and Disability Insurance (NIHDI), 
are an opportunity to explore how this can be achieved in consultation with the GPs. But it is clear that, simultaneously, action 
is needed on the health system level to realize the installation of an accurate quality monitoring system and the necessary 
preconditions for chronic care delivery in primary care (patient registration, staff support, IT support).
Trial Registration: Trial registration number: ClinicalTrials.gov Identifier: NCT00824499
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Background
During the last decade many countries have taken the
first steps towards the adaptation of their health care sys-
tem to a more chronic care oriented system and often the
Chronic Care Model (CCM) has been used as a concep-
tual framework to design the interventions [1]. Most
knowledge on the effect of the introduction of CCM ele-
ments on the quality of chronic care originates from orga-
nizations or countries with a well-structured primary
health care system. Information about efforts made in
other health care systems is still scarce [2,3]. This study
reports on the effectiveness of a CCM-based intervention
in a high-income country with good health care facilities
but with a primary health care system with limited struc-
ture.
In 2003, the Belgian National Institute for Health and
Disability Insurance (NIHDI) commissioned a pilot study
to explore how chronic care could be organized in a more
efficient way in the Belgian health care setting. In the Bel-
gian context, efforts to support patients with chronic dis-
eases are mainly hospital-centered and most chronic
disease patients in primary care are still seen in the con-
text of a system focused on acute care [4,5]. In order to
explore ways to adapt the primary health care system to a
more chronic care oriented system, we set up a four-year
action research project (1st July 2003 - 30th June 2007) in a
well-defined geographical area [6]. Although the study
focused primarily on type 2 diabetes, it was our intention
to develop an approach, applicable to other chronic dis-
eases in primary care. The main characteristics of the
Belgian health care system are summarized in table
1[7,8].
Equity and freedom of choice are high priorities for
health policy. There is no clearly defined gatekeeper func-
tion in place; every citizen has free access to medical spe-
cialists and hospital care, even as the first point of contact
with the health system. Most care providers work as inde-
pendent self-employed health professionals. The patient
pays directly to the care provider and is entitled to a reim-
bursement by his sickness fund. Most services are reim-
bursed at a rate of 75%. In general, patient satisfaction
with the health care system is high [9]. Diabetes teams in
primary care are mostly loose networks of single-handed
care providers. Patients on insulin therapy have the possi-
bility to register in the hospital where they receive care
from a multidisciplinary team (diabetologist, diabetes
educator, dietician). In 2003, the region counted 83 GPs
(GP to population ratio of 1:972), 70% of whom worked in
a single-handed practice, most of them without any sup-
port staff. Structured self-management support programs
were not in place in primary care. Further, there was little
or no coordination regarding diabetes care delivery in the
region and there were no formal shared care models in
place.
We decided to define priorities for change in consulta-
tion with the local care providers (primary and secondary
care) in order to enhance the implementation and the
sustainability of the intervention. In 2003 a written sur-
vey, assessing the strengths and the weaknesses of the
organization of diabetes care was conducted among all
care providers in the region (GPs, specialists, pharma-
cists, dieticians, podiatrists, nurses, home care) involved
in diabetes care. The survey results were discussed with
representatives from the different disciplines (study
group meetings). Two main issues arose from the discus-
sions: the need for more coordination and continuity of
care and the need for more patient support. In consulta-
tion with the region a complex intervention was subse-
quently developed and introduced progressively in the
region (table 2).
The Chronic Care Model was used as a conceptual
framework for priority setting, development and evalua-
tion of the program. The successive steps of the model for
Accelerating Improvement, a scientific method used for
action-oriented learning, were followed and an imple-
mentation strategy was developed based on the current
evidence on the successful implementation of care inno-
vation [11].
The implementation of the CCM components in the
intervention region was assessed in 2007 by the Assess-
ment of Chronic Illness Care (ACIC) survey [12]. The
ACIC survey provides scores corresponding to each of
the six CCM components. In the ACIC, the highest score
("11") indicates optimal support for chronic illness, the
lowest score ("0") corresponds to limited support for
chronic illness. The efforts made in the region resulted in
an increase of 4.05 points in the overall ACIC score, indi-
cating a shift towards a more chronic care-centered sys-
Table 1: Main characteristics of the Belgian health care 
system (2004)
• Financing basis of public health is contribution and tax based
• Health expenditure amounts to 9.3% of gross domestic product (GDP)
• Health care expenditure per capita is 2922 (in US$ PPP)
• Coverage of population by public health is almost universal 
(compulsory)
• Out of pocket payments (proportion of total health expenditure) 
equals 23%
• Payment of GP is mainly fee-for-service with a limited capitation fee 
for registered patients
• GP to population ratio 1:909
• GP has no gatekeeper function; voluntary patient registration with 
a GP (since 1999)
• Approximately 70% of the GPs are working in single-handed 
practices
• About 66% of the GPs are using an electronic medical record (EMR)Sunaert et al. BMC Health Services Research 2010, 10:207
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tem. Figure 1 gives an overview of the scores achieved on
the different CCM components.
In accordance with the needs expressed by the region,
clear progress has been made in aspects related to organi-
zation of health care and self-management support. The
scores for community linkages and decision support pro-
gressed in a similar way. Although these components
were not the main focus of the project the scores
increased as roles in diabetes care were redefined. Conse-
quently, linkages with socio-cultural organizations (e.g.
diabetes patients' organization) were strengthened and
the specialists' role has evolved towards that of a primary
care coach. The scores for delivery system design and
clinical information systems improved the least.
In 2007 we were not able to report on the relation
between the introduction of CCM components and the
quality of diabetes care achieved in the region. The data
on quality of care, collected in a real-life setting, were
useful to guide the process of priority setting but not valid
enough to evaluate the effect of the intervention in the
region. In order to evaluate the effectiveness of the inter-
vention, a follow-up study was financed by the NIHDI.
We reported earlier on the opportunities and barriers
experienced during the implementation of the interven-
tion in the region [13]. The current paper reports on the
effect evaluation.
The paper addresses the following questions:
1. Does the implementation of a CCM-based program
for type 2 diabetes improve the delivery of care (process) in
the intervention region compared to the control region
where usual care continues?
2. Does the implementation of a CCM-based program
for type 2 diabetes improve the quality of care (intermedi-
ate outcome) in the intervention region compared to the
control region where usual care continues?
Methods
Study design
A quasi-experimental design involving a comparable con-
trol region was chosen to evaluate the effect of the inter-
vention in the region [14]. The control region was
selected based on similar geographical and socio-eco-
nomic characteristics and comparable health care facili-
ties as the intervention region. Table 3 summarizes the
main characteristics of the intervention and control
region in 2003 [15].
Data sources
In collaboration with the InterMutualistic Agency (IMA),
an organization in which all Belgian Sickness Funds (n =
7) are represented, and the laboratories from both
regions, a research database was set up in 2008. Data col-
lection and data cleaning were executed following stan-
dardized procedures. The data management process was
coordinated by a senior data manager appointed to the
University of Antwerp (PB) and two members of the
research team (HB, CVDB).
In order to obtain information about population char-
acteristics, medication use, health care consumption
(process of care) and health care costs, we cooperated
with the IMA. In Belgium, all individuals entitled to
health insurance (almost 99% of the population) have to
register with a sickness fund. The services covered by the
compulsory health insurance are described in a nationally
established fee schedule and reimbursement of health
Figure 1 Assessment of Chronic Illness Care (ACIC) in the inter-
vention region* (2003-2007). *The highest score ("11") indicates op-
timal support for chronic illness, the lowest score "0" corresponds to 
limited support.
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Table 2: Introduction of the CCM components in the region 
(1st July 2003 - 30th June 2007)
• Organization of the Healthcare Delivery System
-July 2003: installation of a local steering group
-July 2004: appointment of a program manager
• Community Linkages
-Continuously 2003-2007
• Self-Management Support
-October 2004: individual education program
-June 2005: group-based education program [10]
• Decision Support
-September 2004: distribution of type 2 diabetes guideline
-Continuously 2004-2007: provider education
• Delivery System Design
-December 2004- June 2005: development of an 
interdisciplinary care protocol
-February 2005: support program for the initiation of insulin 
therapy
• Clinical Information Systems
-September 2004 - January 2005: regional audit
-June 2005: regional feedbackSunaert et al. BMC Health Services Research 2010, 10:207
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care costs is linked to specific codes for each service
delivered. An HbA1c test, for example, is registered as
code 540750. By extracting the codes for a number of pre-
defined services we were able to assess the process indi-
cators. In our study, Sickness Fund data were selected for
each patient born in 1966 or earlier, living (at least for
some time) in the region between 1st January 2004 and
31st December 2006 and meeting at least one of the fol-
lowing criteria for the period 2002-2006: reimbursement
of at least one HbA1c test, reimbursement of diabetes-
specific medication, registration in a hospital-based dia-
betes centre. VDV coordinated the IMA data collection.
In order to obtain information about intermediate out-
comes (HbA1c, total cholesterol) we invited the laborato-
ries from both regions (ambulatory and hospital-based)
to provide data. Ten (six in the intervention and four in
the control region) of the eleven invited laboratories,
agreed to participate. The non-participating laboratory
owned only data from a small number of patients referred
by one GP (control region). The laboratories were asked
to provide data from each patient living (at least for some
time) in the region between 1st January 2004 and 31st
December 2006 and having at least one HbA1c measure-
ment performed during the period 2002-2006. CVDB
coordinated the data collection process among the labo-
ratories.
T h e  l a bo r a t o ry  da t a  w e r e  s u bs eq u e n t l y  l i n k ed  t o  t h e
IMA data by a Trusted Third Party (TTP) using a unique
identification code. The process of data extraction, data
linking and data analysis was approved by the Sectoral
Committee of Social Security and Health and by the
Commission for the protection of the Privacy (authoriza-
tion 08/05/07, 06/05/2008 and 18/08/2008; SCSZ/07/
076) [16].
Study population
The intervention population included all type 2 diabetes
patients in the defined area. Since the Sickness Funds do
not register diagnostic information, we had to identify
persons with type 2 diabetes using indirect criteria for
diabetes (table 4) [17]. To make sure that persons selected
in the cohort were "real" type 2 diabetes patients, we only
included patients who were on antidiabetic medication in
2003. Patients treated with 3 or more insulin injections a
day in 2003 were excluded from the study cohort in order
to exclude most of the diabetes type 1 patients given the
fact that they were not the target group of this interven-
tion. In 2003, on average, 84% of the diabetes type 1
patients in Belgium were treated with 3 or more insulin
injections (personal communication ND, Institute of
Public health (IPH)) [18].
Diabetes patients who moved to a more complex insu-
lin scheme during the study period were not excluded. To
make the exposure time to the intervention comparable
for all patients, we only included persons who were
exposed to the intervention from the start (patients living
in the region in 2004). Persons who moved or died during
the intervention period were not excluded from the study
cohort. Patients who started antidiabetic therapy after 1st
January 2004 were excluded in order to limit bias by the
inflow of patients whose treatment had been adjusted in
consequence of the intervention.
Principal outcomes
We defined a set of quality indicators, six process and
three outcome indicators, to evaluate the effect of the
intervention in the region. To define the set of quality
indicators we relied on the indicators currently used in
Table 3: Baseline characteristics of the intervention and the 
control region (2003)
Intervention 
region
Control region
Geographical
Inhabitants 76,799 68,663
Population density (n/km2) 984 827
Socio-economic
Female population (%) 50.8 50.6
Mean age (years) 41,32 40.63
Population over 65 years (%) 18.1 16.2
Foreigners (%) 1.9 3.5
Employment rate (men) (%)* 75.2 74.9
Employment rate (women) (%)* 61.5 58.5
Mean income (%)** 104.7 98.4
Health care facilities
GP to population ratio 1:972 1:1069
Hospitals in the region 2 2
Number of endocrinologists 3 2
*Proportion of men and women employed in relation to the available 
workforce in the region.
**Mean income in relation to the mean income in Flanders.
Table 4: Criteria used to extract the study cohort
Inclusion criteria
-living in the region in 2004
-born in 1966 or before (≥40 years in 2006)
-reimbursement of at least one prescription for antidiabetic 
agents (oral therapy, insulin therapy) in 2003 (year before the 
start of the intervention)
Exclusion criteria
-≥3 daily insulin injections (before 01/01/2004)Sunaert et al. BMC Health Services Research 2010, 10:207
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the Quality and Outcomes Framework (QOF) and the
availability of the data in the research database (table 5)
[19,20].
We included the prescription of statin therapy as a pro-
cess indicator given the fact that cardiovascular risk pre-
vention was a priority for change in the region. The
prescription of an influenza vaccination (also included in
the QOF) was added in order to evaluate the attention for
the overall prevention strategies in the region. The cut-
offs of the outcome quality indicators were defined
according to the cutoffs currently used in the Quality and
Outcomes Framework (QOF).
The process indicators were defined using the reim-
bursement codes in the Sickness Fund data. Concerning
the intermediate outcome indicators, the data provided
by the laboratories were used. All HbA1c and total cho-
lesterol tests performed during the intervention period
(real-life measurements) were included in the analysis.
Since 2002, Belgian laboratories participate in an External
Quality Assessment (EQA) program, organized by the
Scientific Institute of Public Health (IPH) [21]. All partic-
ipating laboratories use Diabetes Control and Complica-
tions Trial (DCCT)-aligned methods to determine
HbA1c and since 2004, the performance quality of Hba1c
t e s t i n g  h a s  be e n  g ood  t o  v e ry  g o od  i n  a l l  l a bo r a t o r i e s
involved. The determination of total cholesterol is less
prone to measurement errors, and for this reason total
cholesterol test results can be used for analysis purposes
since 2002 (personal communication CVC, IPH).
Statistical analysis
Statistical analysis was supervised and performed by
members (AC, AI, GV) of the Leuven Statistics Research
Centre, an institution experienced in longitudinal data
analysis.
Baseline characteristics of the diabetes population in
both regions were compared using a t-test for continuous
variables and a Chi-squared test for dichotomous vari-
ables respectively. Means and standard deviations were
reported for continuous variables, proportions for
dichotomous variables.
In order to study the evolution of the dichotomous pro-
cess indicators in both regions, a Generalized Estimating
Equations (GEE) model was used [22]. This model
accounts for the clustering of data within patients
(repeated measures). In the model, the achievement of a
specific target in one year (e.g. HbA1c test performed in
2006), was the dependent variable, whereas time (before
and after the intervention period) and group (interven-
tion vs. control region) were the independent variables.
The evolution in both regions was compared using a test
for interaction between time and region.
Continuous outcome indicators (HbA1c and total cho-
lesterol) were analyzed with linear mixed models, with
the patient as random effect [23]. All patients, for whom
at least one HbA1c and/or total cholesterol measurement
were available during the study period, were included in
the analysis. The analysis of HbA1c measures included
80% of the patients, the analysis for cholesterol measures
77% of the patients. For those patients, all HbA1c and
total cholesterol measurements received from the labora-
tories during the study period ("real life" measurements)
were included. In the model, logarithmic transformed
HbA1c measurements and total cholesterol measure-
ments were the dependent variables, time and group
(intervention vs. control region) the independent vari-
ables. Comparison of the evolution in both regions was
done using a test for interaction between time and region.
All analyses were performed using SAS (version 9.2)
and a significance level of 5% was used. Evaluations were
done according to the intention-to-treat principle.
Results
Baseline characteristics of the diabetes population in the 
intervention and control region
In total 4,174 persons who met the defined criteria were
selected from the database; 2,425 patients (52.9% women)
Table 5: Set of nine quality indicators
Quality indicator Data source
Indicators of care process IMA
▪ The percentage of patients with at least 
one assessment of HbA1c during the last 
12 months
▪ The percentage of patients with at least 
one assessment of cholesterol during the 
last 12 months
▪ The percentage of patients with a 
prescription for statin therapy during the 
last 12 months
▪ The percentage of patients with at least 
one assessment of micro-albuminuria 
during the last 12 months
▪ The percentage of patients with a 
prescription for influenza vaccination 
during the last 12 months
▪ The percentage of patients with at least 
one assessment by an ophtalmologist 
during the last 12 months
Indicators of intermediate outcome of care Laboratories
▪ The percentage of patients with 
diabetes in whom HbA1c is ≤7.5%
▪ The percentage of patients with 
diabetes in whom HbA1c is ≤10%
▪ The percentage of patients with 
diabetes whose total cholesterol is ≤190 
mg/dlSunaert et al. BMC Health Services Research 2010, 10:207
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with a mean age of 67.5 from the intervention region and
1,749 patients (55.7% women) with a mean age of 67.4
from the control region. Table 6 summarizes the baseline
characteristics of both study cohorts.
There were no statistically significant differences
regarding, demographic, socio-economic and diabetic
characteristics at the baseline. Both study groups only dif-
fered significantly regarding the percentage of patients
registered in a hospital-based diabetes centre, although
the absolute difference was small.
Evolution of the process indicators
Table 7 summarizes the evolution of the process indica-
tors from baseline until the end of 2006.
The proportion of patients with at least one HbA1c
assessment in the last 12 months increased significantly
in the intervention region, although the improvement
was moderate. Significantly more patients had their urine
tested for micro-albuminuria in 2006, but this evolution
was not significantly different from the one in the control
region. Most progress was made in the proportion of
patients who were prescribed statin therapy. Cardiovas-
cular risk assessment and the prescription of statin ther-
apy according to the guidelines were priorities for change
in the region. Both in the intervention and in the control
region, significantly more patients were prescribed statin
therapy in 2006, although the rise was significantly
greater in the intervention region (p = 0.0002). The other
process indicators remained almost status quo. In 2006,
as in 2003, significantly more patients in the intervention
region (p = 0.0061) received an influenza vaccination.
However, the control region evolved better (p = 0.0462).
According to the IMA data 94% of the patients received at
least one HbA1c test during the study period, 96% at least
one cholesterol test. These figures reflect that there are
little or no patients who receive no care at all. However,
the percentage of patients receiving an annual review as
recommended in the guidelines remains low. Especially
the assessment of long-term diabetes complications
remains suboptimal.
Evolution of the intermediate outcome indicators
Mean HbA1c and cholesterol levels decreased signifi-
cantly during the study period, both in the intervention
and in the control region (p < 0.001; table 8). The
decrease in mean cholesterol level was significantly
greater in the intervention region (p = 0.0021).
The improvement in mean HbA1c and cholesterol lev-
els was reflected in the percentage of patients achieving
intermediate outcome targets at the end of 2006 (table 9).
One of the priorities in the intervention region was to
increase the proportion of patients with an HbA1c value
of 7.5 or less. In 2006, there was a significant increase in
patients achieving an HbA1c level of 7.5 or less in the
intervention region (p < 0.0001) but the progression was
not significantly different from the one in the control
region. The proportion of patients achieving a cholesterol
level of 190 mg/dl or less increased significantly more in
the intervention region. Most probably, this evolution
was due to the significant increase in statin use.
Discussion
Summary of main findings
T h i s  s t u d y  r e po rt s  o n  t h e  e f f e c t  o f  a n  a c t i o n  r e s e a r c h
project (complex intervention; table 2) on the quality of
care for type 2 diabetes patients. At the end of 2006
improvements were observed in five of the nine defined
quality indicators in the intervention region, three of
which (HbA1c assessment, statin therapy, cholesterol tar-
get) improved significantly more than in the control
region. The systematically assessment of long-term dia-
betes complications (nephropathy and retinopathy
Table 6: Baseline characteristics of the type 2 diabetes populations (2003)
Intervention region
N = 2,425
Control region
N = 1,749
P value*
% female population 52.87 55.69 0,071
Mean age (years) 67.54 ± 11.08 67.40 ± 10.73 0,692
% ≥75 28.46 27.73 0,608
% reduced co-payments 32.91 31.62 0,380
% registered with GP 62.39 65.01 0,083
% registered in diabetes centre 5.3 3.9 0.039
% insulin therapy 15.67 15.44 0,838
Mean HbA1c (01/01/2004) 7.55(7.48-7.62) 7.44(7.34-7.53) 0.057
Mean total cholesterol (01/01/2004) 199.07(197.01-201.13) 199.44(197.03-201.90) 0.812
% hospitalisation during the last year 23.71 24.71 0,600
*t-test for continuous variables; Chi-square test (MH Chi-Square) for dichotomous variablesSunaert et al. BMC Health Services Research 2010, 10:207
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screening) remained insufficient. In 2006 only 26% of the
patients had their urine tested for micro-albuminuria and
only 36% had consulted an ophthalmologist. Although
the progression was moderate, there may be room for
optimism, given the fact that the effect of the interven-
tion was not yet at its maximum. Due to the chosen
methodology, i.e. action research, the different compo-
nents of the intervention were introduced progressively
in the region and participation of patients and care pro-
viders increased gradually.
Strengths of the study
Quality data are scarce in Belgium and regular monitor-
ing of diabetes care is limited to patients registered in a
hospital-based diabetes centre [24,25]. A key strength of
the study is that, for the first time in Belgium, quality data
were available for all type 2 diabetes patients in a well-
defined region. As a consequence of the use of the IMA
data to define the study cohorts, recruitment bias was
prevented. In this way the data reflect "real-life" quality of
diabetes care achieved for diabetes patients on medica-
tion.
Another important strength of the study is the avail-
ability of data from a control region with similar geo-
graphical and socio-economic characteristics and health
care facilities comparable to those in the intervention
study. The chosen study design allows for a comparison
of the evolution in the intervention region with the evolu-
tion in a control region, where usual care was continued.
In this way time trends could be taken into account.
Limitations of the study
The Sickness Funds do not register diagnostic informa-
tion. For this reason diabetes patients could only be
selected through indirect criteria. As a consequence the
study gives no information about type 2 diabetes patients
treated with lifestyle therapy. Furthermore, we excluded
patients treated with 3 or more insulin injections a day
(8.6% of the diabetes patients on medication in 2003), in
order to limit the presence of type 1 diabetes patients in
the study cohorts. In doing so we inevitably also excluded
type 2 diabetes patients treated with an intensive insulin
scheme, accounting for about a quarter of the type 2
patients treated with insulin in 2003 (personal communi-
Table 7: Changes in process indicators°
% of patients receiving services Evolution 2003-2006
2003 2006 P value for the Δ
in both regions *
P value for the Δ
between both regions**
HbA1c test
Intervention region 65.52 71.25 +5.73 (p < 0.0001) p = 0.0117 (1)
Control region 68.58 70.60 +2.02 (p = 0.0580)
Total Cholesterol test
Intervention region 72.53 73.33 +0.80 (p = 0.3888) p = 0.0190 (1)
Control region 74.21 69.14 -2.59 (p = 0.0178)
Statin therapy
Intervention region 27.07 45.15 +18.08 (p < 0.0001) p = 0.0002 (1)
Control region 25.15 37.54 +12.39 (p < 0.0001)
Micro-albuminuria test
Intervention region 20.57 25.96 +5.39 (p < 0.0001) p = 0.1325
Control region 15.71 18.34 +2.63 (p = 0.0037)
Influenza vaccination
Intervention region 57.43 58.14 +0.71 (p = 0.4627) p = 0.0462 (2)
Control region 50.35 53.91 +3.56 (p = 0.0007)
Ophthalmologist visit
Intervention region 34.72 36.10 +1.38 (p = 0.1360) p = 0.9300
Control region 31.18 32.36 +1.18 (p = 0.2653)
°GEE model; Δ = evolution; *P value for the evolution (2003-2006) in the intervention and control region; **P value for the evolution (2003-
2006) between the intervention and control region, (1) significantly greater change in the intervention region (2) significantly greater change 
in the control regionSunaert et al. BMC Health Services Research 2010, 10:207
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cation ND, IPH). Diabetes patients who moved to a more
complex insulin scheme during the study period were not
excluded. This information is of particular interest when
our study results are compared with these of other study
populations.
However, we assume that the limitations related to the
inclusion and exclusion of patients were comparable for
both study cohorts and have not affected the main con-
clusions. Moreover, the prevalence of type 2 diabetes in
both study cohorts is very similar to the prevalence
recorded in previous studies in Belgium, indicating that
no systematic fall out of patients occurred [26].
The use of administrative data to define the quality
indicators, implies that the current study gives no infor-
mation about some important quality indicators only
available via medical records (e.g. smoking, weight con-
trol and blood pressure). The data, used to define the
quality indicators, are administrative data, primarily
meant to reimburse patients and care providers. During
the process of recoding these data, some errors may have
occurred. Again, there is no reason to presume that this is
different for the two study cohorts. Another limitation of
the use of administrative data is the delay with which
these data are available for evaluation. In Belgium,
patients and care providers can declare their health care
bills until two years after the service has been delivered.
For this reason the study could not start until 2008.
Table 8: Changes in intermediate patient outcomes°
Intervention period Δ
01/01/04-01/01/07
P value*
01/01/2004 01/01/2007
HbA1c (%)
Intervention 7.55(7.48-7.62) 7.06(7.00-7.12) -0.49(p < 0.0001) 0.4207
Control 7.44(7.34-7.53) 6.90(6.83-6.98) -0.54(p < 0.0001)
TC (mg/dl)
Intervention 199.07(197.01-201.13) 173.94(171.85-176.04) -25.13(p < 0.0001) 0.0021 (1)
Control 199.44(197.03-201.90) 180.60(177.83-183.41) -18.84(p < 0.0001)
°linear mixed model; Δ = evolution; *P value for the evolution between the intervention and control region, (1) significantly greater change 
in the intervention region (2) significantly greater change in the control region
Table 9: Changes in intermediate outcome indicators°
% of patients achieving targets Evolution
01/01/04 01/01/07 P value Δ
in both regions *
P value Δ
between both regions**
HbA1c ≤ 7,5%
Intervention 55.40 61.68 +6.28 (p < 0.0001) 0.3425
Control 56.67 65.04 +8.37 (p < 0.0001)
HbA1c ≤ 10%
Intervention 93.13 93.89 +0.76 (p = 0.3561) 0.1479
Control 93.63 95.94 +2.31 (p = 0.0184)
TC ≤ 190 mg/dl
Intervention 40.49 58.81 +18.32 (p < 0.0001) 0.0305 (1)
Control 41.15 53.95 +12.80 (p < 0.0001)
°GEE model; Δ = evolution; *P value for the evolution in the intervention and control region; **P value for the evolution between the 
intervention and control region, (1) significantly greater change in the intervention region (2) significantly greater change in the control 
regionSunaert et al. BMC Health Services Research 2010, 10:207
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Results in relation to the CCM elements targeted
The ultimate purpose of the study was to inform health
policy leaders about effective strategies to adapt primary
health care to a more chronic care oriented system. In
this light the moderate gain in quality of diabetes care in
relation to the 4.05 progress in the overall ACIC score
needs some reflection. Although the evaluation of a com-
plex intervention is challenging given the fact that com-
ponents of the intervention may act both independently
and interdependently, we tried to explain the study
results in relation to the different CCM components tar-
geted in the intervention [27]. More insight in this rela-
tionship is also crucial in the light of future actions. There
is a growing body of literature on the relation between
investments in components of the CCM and effects on
quality of chronic care [28-30]. The rather limited prog-
ress in quality of care in relation to the 4.05 progress in
the overall ACIC score can probably be explained on the
one hand by the nature of the elements of the CCM we
have targeted (Figure 1) and by the chosen methodology
(action research) on the other hand. In accordance with
the needs expressed by the region we have spent a lot of
effort strengthening primary care at the meso level (pro-
gram manager, steering group, study groups), which
resulted in a clear increase of the ACIC scores for organi-
zation of health care and community linkages. These
efforts were indispensable for the coordination of diabe-
tes care in the region and the facilitation of the quality
improvement process but probably did not have a direct
effect on the quality of care at the patient level. The
investments in decision support (guideline dissimination,
provider education, regional feedback, support by spe-
cialists) have certainly raised the awareness regarding the
need for a more stringent therapeutic approach of diabe-
tes (timely upgrading of diabetic medication and cardio-
vascular risk assessment). Mean HbA1c and lipid levels
decreased significantly in the intervention region during
the study period. The similar evolution of the HbA1c lev-
els in the control region can probably be explained by a
time trend. The guideline type 2 diabetes, first introduced
in the intervention region, was introduced in all regions
in Flanders in 2005, accompanied by an intensive infor-
mation campaign. Regarding the evolution of the lipid
levels, there is an indication that the positive trend was
already ongoing before the study started (unpublished
data). The intervention has given an extra boost regard-
ing statin prescription. In consultation with the region an
education program, integrated in primary care, was
launched for diabetes patients on lifestyle and/or medica-
tion therapy. The potential benefit of the introduction of
the program in the region is probably underestimated in
the selected study cohort. On the one hand, due to the
kind of data available for evaluation, an important target
group for the education program, i.e. newly diagnosed
patients, was excluded from the current study cohort. On
the other hand, due to the methodology of action
research, the participation of patients increased gradually
and the effect of the program was certainly not yet at its
maximum. The project had only a limited impact on the
organization of diabetes care at the practice level (deliv-
ery system design) and the use of information technology
(IT) (clinical information systems) in practice, e.g. in 2007
30% of the GPs mentioned to have some diabetes register
(mostly on paper), but this list was not routinely used to
plan follow-up or other actions (survey among GPs,
2007). The limited progress in these components proba-
bly explains the poor results regarding the assessment of
long-term diabetes complications.
Quality of care in relation to international trends
As mentioned above, this is the first time that quality data
were available for all type 2 diabetes patients from two
regions in Belgium. As a result these data reflect the qual-
ity of care achieved in a country where initiatives to sup-
port chronic care were, until recently, mainly hospital-
based and where primary care teams are usually flexible
and loose networks of single-handed care providers [31].
A comparison of the baseline data of a recent review of
published observational studies in primary care (same
t i m e  s p a n  a s  o u r  s t u d y )  w i t h  t h e  b a s e l i n e  d a t a  o f  o u r
study, revealed similar results regarding intermediate
outcome indicators [32]. As to the process indicators, the
same trends were observed as in our study. The standard
of care achieved for the more complex process indicators
(e.g. retinal screening) was lower than for the simple pro-
cess indicators (e.g. HbA1c assessment), although in gen-
eral our scores were lower. This can partly be explained
by the fact that in our study compliance was assessed over
the previous 12 months while this was 15 months in most
of the studies cited in the review.
Another interesting comparison source is a study eval-
uating the effect of the QOF on diabetes care in a whole
county (Shropshire) in the same time span as our study
[33]. In 2004, similar quality data were observed as in our
study. In 2006, two years after the introduction of the
QOF, the quality data improved substantially more than
in our study (e.g. HbA1c recording increased from 75% to
94%; retinal screening from 47% to 84%). The QOF, a pay-
for-performance scheme based on meeting targets for the
quality of clinical care, was introduced in England in
2004. In general this scheme has accelerated quality
improvement in different aspects of clinical care,
although some authors also warn against unintended
consequences, including reductions in the quality of care
not linked to incentives and in the continuity of care [34].
The introduction of the QOF was accompanied by
important investments in primary care [35]. Further-
more, in England, primary care has a long tradition ofSunaert et al. BMC Health Services Research 2010, 10:207
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multidisciplinary teams and patients are registered with a
specific primary care facility, factors which facilitate qual-
ity improvement.
Implications for health policy and future research
The results of the current study reflect the fact that the
project succeeded in strengthening primary care at the
meso level but had only limited impact on the organiza-
tion of care at the practice level (delivery system design
and clinical information systems). This became especially
apparent in the inadequate monitoring of long term com-
plications. The quality level observed in the intermediate
outcomes is acceptable, which reflects the continuous
investments in quality improvement at provider level in
Belgium [36]. However, there is still room for improve-
ment (e.g. +/- 25% of the patients has an HbA1c level ≥8%
in 2006). Comparable results have been seen in other set-
tings starting to adapt their care system to a more chronic
care oriented system as e.g. described in an evaluation of
CCM implementation in primary care in the US (Minne-
apolis-St Paul Metropolitan region). Implementing the
CCM elements in a system originally set up to deliver
acute and episodic care, takes time. It demands to switch
the focus of quality improvement efforts from the indi-
vidual level of patients and care providers to the system
level. Further, strong leadership and a careful change
management are continuous needed [37]. Future research
initiatives in the Belgian context need to explore how the
practice level can be adapted to a more chronic care ori-
ented approach. The regional network, as established in
our project, is an ideal platform to start up further quality
improvement projects. The NIHDI has recently decided
to finance the establishment of comparable networks in
other regions in Belgium. Currently (since July 2009) sev-
eral regions have started to appoint program managers.
We already reported on the opportunities and barriers
regarding chronic care organization in the Belgian con-
text, and emphasized the need for clear action on the
health system level regarding the installation of a quality
monitoring system on the one hand and the strengthen-
ing of recent initiatives to facilitate chronic care delivery
in primary care (patient registration, staff support, IT
support) on the other hand. These are essential precondi-
tions for adequate chronic care.
The effect of the introduction of an education program
for diabetes patients in the region is probably not yet
measurable in this study cohort. One of the main
researchers (HB) is currently evaluating the effect of the
education program on the quality of care among patients
who attended the program. Future research needs to
explore how this program can best be continued in pri-
mary care.
Conclusion
This study reports on the relation between the imple-
mentation of CCM elements and the quality of diabetes
care achieved in a country where the efforts to adapt pri-
mary care to a more chronic care oriented system are still
at a starting point. Although the overall ACIC score
increased from 1.45 to 5.5, the improvement in the qual-
ity of diabetes care was moderate. Strengthening primary
care at the meso level contributed to a better coordina-
tion of diabetes care, but probably did not influence the
quality of care at the patient level. The project had only a
limited impact on the organization of diabetes care at the
practice level (delivery system design) and the use of
information technology (IT) (clinical information sys-
tems) in practice. Future research initiatives in the Bel-
gian context need to explore how the practice level can be
adapted to a more chronic care oriented approach. The
regional networks, as they are financed now by the
NIHDI, are an opportunity to explore how this can be
achieved in consultation with the GPs. But it is clear that,
simultaneously, action is needed on the health system
level to realize the installation of an accurate quality
monitoring system and the necessary preconditions for
chronic care delivery in primary care (patient registra-
tion, staff support, IT support).
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